Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-INHBE · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: ARO-INHBE | EXPERIMENTAL | ARO-INHBE in single (Day 1) or multiple (Days 1 and 29) ascending doses |
| Part 1: Placebo | PLACEBO_COMPARATOR | Placebo in single (Day 1) or multiple (Days 1 and 29) matching doses |
| Part 2: ARO-INHBE + Tirzepatide | EXPERIMENTAL | ARO-INHBE at ascending doses on Days 1 and 29 plus weekly doses of tirzepatide (2.5 to 5 milligrams \[mg\]) starting Day 15 through Day 169 |
| Part 2: Placebo + Tirzepatide | PLACEBO_COMPARATOR | Placebo dose on Days 1 and 29 plus weekly doses of tirzepatide (2.5 to 5 mg) starting Day 15 through Day 169 |
| Part 3: ARO-INHBE | EXPERIMENTAL | ARO-INHBE on Days 1, 85, 169, and 253 |
| Part 3: Placebo | PLACEBO_COMPARATOR | Placebo doses on Days 1, 85, 169, and 253 |
| Part 3: ARO-INHBE + Tirzepatide | EXPERIMENTAL | ARO-INHBE at ascending doses on Days 1, 85, 169, and 253 plus weekly doses of tirzepatide (2.5 to 15 mg \[or the maximally tolerated dose\]) starting Day 15 through Day 365 |
| Part 3: Placebo + Tirzepatide | PLACEBO_COMPARATOR | Placebo doses on Days 1, 85, 169, and 253 plus weekly doses of tirzepatide (2.5 to 15 mg \[or the maximally tolerated dose\]) starting Day 15 through Day 365 |
| Name | Type | Description |
|---|---|---|
| ARO-INHBE | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | Calculated volume to match active treatment by SC injection |
| Tirzepatide | DRUG | SC injection |
Inclusion Criteria: * Obesity, defined as Body Mass Index (BMI) between 30 to 50 kilograms (kg)/square meter (m\^2) at Screening * At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification * Type 2 diabetes mellitus for at least 6 months prior to Screening, with gl...
Top 20 of 32 competitors
ARO-INHBE is an investigational drug being developed for the treatment of obesity. It is currently in Phase 1 clinical development and is being studied in adults with obesity, with and without type 2 diabetes mellitus.
ARO-INHBE is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR.
ARO-INHBE is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants.
ARO-INHBE is being evaluated in a Phase 1 clinical trial with the identifier NCT06700538. This is a first-in-human study in adults with obesity, with and without type 2 diabetes mellitus, and is currently recruiting participants in Australia and New Zealand.
Yes, ARO-INHBE is a small molecule therapeutic. It is being developed as a treatment for obesity and is currently in Phase 1 clinical trials.